Nordic Adalimumab Biosimilar Market Size & Outlook, 2026-2034

Nordic Adalimumab Biosimilar Market Insights

As per Deep Market Insights insights, the Nordic Adalimumab Biosimilar Market stood at USD 30.27 Million in 2025 and is anticipated to grow to USD 53.48 Million by 2034.
The Nordic market is expected to advance at a CAGR of 6.48% from 2026 through 2034.
In 2025, Adalimumab biosimilars accounted for the highest share of the By Type market size.
During the forecast period, Adalimumab biosimilars is set to register the highest growth, making it the most lucrative By Type segment.

In 2025, Nordic represented 1.07% of the overall global Adalimumab Biosimilar Market size.
United States is projected to lead the global Adalimumab Biosimilar Market size by 2034.
Across Europe, Germany is anticipated to hold the dominant position in market size by 2034.
United Kingdom is forecasted to expand at the fastest pace in Europe, attaining USD 213.76 Million by 2034.

Report Scope	Details
Base Year for Study	2025
Study Period	2022-2034
Historical Period	2022-2024
Forecast Period	2026-2034
Market Size In 2025	USD 30.27 Million
Market Size In 2034	USD 53.48 Million
Largest segment	Adalimumab biosimilars
Units	Revenue in USD Million
CAGR	6.48% (2026-2034)
Segmnetation Covered
By Type	Adalimumab biosimilars Interchangeable biosimilars High-concentration formulations Low-concentration formulations
By Indication	Rheumatoid arthritis Psoriasis Crohn’s disease Ulcerative colitis
By Route of Administration	Subcutaneous Prefilled syringes Auto-injectors Hospital administration
By End User	Hospitals Clinics Homecare Specialty pharmacies
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

By Type	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Adalimumab biosimilars	XX.x	XX.x	XX.x	12.37	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Interchangeable biosimilars	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
High-concentration formulations	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Low-concentration formulations	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

By Indication	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Rheumatoid arthritis	XX.x	XX.x	XX.x	12.82	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Psoriasis	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Crohn’s disease	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Ulcerative colitis	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

By Route of Administration	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Subcutaneous	XX.x	XX.x	XX.x	12.12	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Prefilled syringes	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Auto-injectors	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Hospital administration	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

By End User	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Hospitals	XX.x	XX.x	XX.x	12.13	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Clinics	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Homecare	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Specialty pharmacies	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x